DPx Holdings B.V., privately owned by JLL Partners and Royal DSM, has reached a definitive agreement to acquire all shares of Gallus BioPharmaceuticals, LLC, a contract manufacturing company specializing in biologics and current portfolio company of Ridgemont Equity Partners.
Pharmaceutical Product Development, LLC (PPD) today announced the appointment of Robert Hureau...
Metrics Contract Services, a full-service contract pharmaceutical formulation development and...
Packaging Coordinators has reached a definitive agreement to acquire Penn Pharmaceutical...
Oncology drug developer, CanTx Inc., and its parent company, Novogen Ltd., today announced that they have named two key contract manufacturing organizations (CMOs) to produce clinical batches of the experimental anti-cancer drug, Cantrixil.
Aptuit Names Executive VP, Business Development & Marketing; Enhances Sterile Drug Product CapabilitiesJuly 16, 2014 11:33 am | News | Comments
Aptuit LLC has appointed Paul D. Overton, Ph.D., as Executive Vice President, Business Development and Marketing, making him responsible for all of Aptuit’s sales and marketing activities.
Chiltern and Ockham, two full-service contract research organizations (CROs), today announce that Chiltern has acquired 100% of Ockham and that the companies will merge their operations. The combined company will be called Chiltern. Ockham's management team will join the management of the enlarged group, thus ensuring a seamless continuation of high quality services.
Mention the terms ‘cell therapy’ or ‘regenerative medicine’ and many in the general public are still confused as to what those terms actually mean. But those in the know understand that cell therapy is a growing and thriving industry, with great potential to change the face of modern healthcare.
AAIPharma Services Corp., a global provider of pharmaceutical analytical testing, product development and manufacturing services, and Cambridge Major Laboratories, Inc., a provider pharmaceutical API development and manufacturingservices, announced the appointment of Stephan Kutzer, Ph.D. as Chief Executive Officer (CEO), effective August 1, 2014.
Metrics Inc. has expanded its already robust options for enhancing drug bioavailability thanks to the recent acquisition of a BÜCHI B-290 Mini Spray Dryer. The dryer’s core capability is rendering powder from a solution, said Brad Gold, Ph.D., vice president of pharmaceutical development.
Bioanalytical Systems, Inc. (BASi) today announced the appointment of Jeffrey Potrzebowski as Chief Financial Officer and James S. Bourdage, Ph.D., as Vice President Bioanalytical Operations.
Xcelience announced today the opening of a 3,000 square foot facility in Birmingham, UK, making it the first small to mid-sized American CDMO to launch international operations. The new plant will become a gateway for the Florida-based company’s clinical packaging and distribution services in the UK, Europe and abroad.
Frontage Labs today announced plans to expand its chemistry, manufacturing and controls (CMC) facility in Exton, P.A. The expansion includes significant incremental capacity to existing services, and will also provide Frontage with additional room for future growth.
Bristol-Myers Squibb and Syngene International, India’s largest contract research organization, today announced a five-year extension of their drug discovery and development collaboration in India.
AMRI has signed a definitive agreement to acquire all of the outstanding membership interests of Oso Biopharmaceuticals Manufacturing, for $110M in cash. OsoBio is a contract manufacturer of highly complex injectable drug products, including sterile liquid, suspension and lyophilized formulations.
WuXi PharmaTech today announced that its manufacturing subsidiary, Syn-The-All Pharmaceutical Co., Ltd. (STA), has begun operation of a high-potency active pharmaceutical ingredient (HPAPI) laboratory in Shanghai, thereby adding HPAPI processing to its portfolio of services.
PAREXEL International, a global biopharmaceutical services organization, today named Dr. Sy Pretorius its Chief Scientific Officer. Dr. Pretorius currently serves as the company's Corporate Vice President and Worldwide Head of Early Phase, and will continue in that capacity in addition to assuming his expanded responsibilities.
Relypsa, a biopharmaceutical company, today announced that it has entered into a multi-year commercial manufacturing and supply agreement with DSM Fine Chemicals Austria NFG GMBH & Co. KG for the active pharmaceutical ingredient for patiromer, the company's novel polymer in development for the treatment of hyperkalemia.
Lannett Company announced that it has entered into distribution and contract manufacturing services agreements with Sunshine Lake LLC, the U.S. subsidiary of the HEC Pharm Group (HEC) of Shenzhen, Guangdong Province, China.
The May issue of Pharmaceutical Processing profiles PCI, a contract developer and manufacturer of custom NCEs, fine chemicals and generic APIs based in Newburyport, MA. We also take a look at the critical success factors clients evaluate when choosing a CMO. Our manufacturing services Q&A discusses current trends, issues and the future of pharmaceutical processing services. In addition we cover tablet coating, single-use technologies and QbD in test method development and validation.
Boston Therapeutics Signs Agreement With Patheon to Manufacture Pharmaceutical-Grade BTI-320 TabletsMay 6, 2014 8:02 am | News | Comments
Boston Therapeutics and its Hong Kong-based strategic partner Advance Pharmaceutical Company, have signed an agreement with Patheon to manufacture pharmaceutical-grade tablets of the company's lead product candidate BTI-320, a compound designed to reduce post-meal elevation of blood glucose.
Outsourcing continues to be an integral part of biopharmaceutical manufacturing, and facilities are outsourcing activities today at heightened levels. As a result, the contract manufacturing organization (CMO) community has seen an expansion of opportunities, leading to increased competition. In this science and technology-driven environment, how can CMOs separate themselves from the pack?
Quintiles, a provider of biopharmaceutical development and commercial outsourcing services, and Biogen Idec have entered into a five-year strategic clinical development agreement. The multi-year collaboration is designed to leverage the expertise and experience from both organizations to optimize Biogen Idec’s clinical development processes.
PCI, Inc. a contract manufacturing and research organization based in Newburyport, MA that develops and manufactures NCEs, generic APIs and fine chemicals has grown from a small start-up to a company that can now take a product all the way from development to commercial production in a smooth and seamless process for its clients.
Albany Molecular Research Inc. announced Wednesday that it will close its 12-year-old facility in Cicero on July 15. Some employees will be transferred to Albany, Cedarburg, Wis., England and India.
The April issue of Pharmaceutical Processing profiles Reed-Lane, a contract packager of solid-dosage products based in Wayne, NJ. Additional articles on contract services and outsourcing topics include a look at the global biosimilars market and an update on solid dosage manufacturing services. In addition, the benefits of using ready-to-fill vials is explored. Other topics covered in this issue include packaging inspection, anti-counterfeiting technologies, lab design and expediting drug development.
UPM, a division of Gregory Pharmaceutical Holdings, Inc., has reached an agreement with Amerigen Pharmaceuticals, Inc. to commercially manufacture two ANDA products for a 10 year supply term.
Approximately 25% of drugs in development worldwide are classified as highly potent, with this percentage expected to grow over the coming years. While such highly potent compounds can have significant benefits in the treatment of certain medical conditions, they present substantial challenges to the pharmaceutical industry.
No two packaging projects are alike and in order to make it all work and to keep everything on track and everyone happy you need to have a flexible, responsive and quality-driven organizations. Reed-Lane has deftly combined these qualities along with recent investments to create a truly flexible contract packaging operation.
- Page 1